Are there regional differences in the management of colon cancer in France?

被引:8
作者
Phelip, JM
Grosclaude, P
Launoy, G
Colonna, M
Danzon, A
Velten, M
Tretarre, B
Bouvier, AM
Faivre, J
机构
[1] INSERM, Cote Or & Saone & Loire Canc Registry, CRI 95 05, F-21000 Dijon, France
[2] Fac Med Dijon, DRED 1789, F-21000 Dijon, France
[3] Tarn Canc Registry, F-81000 Albi, France
[4] Univ Hosp Caen, Calvados Canc Registry, F-14000 Caen, France
[5] Isere Canc Registry, F-38240 Meylan, France
[6] Univ Hosp Besancon, Doubs Canc Registry, F-25030 Besancon, France
[7] Bas Rhin Canc Registry, Fac Med, F-67085 Strasbourg, France
[8] Ctr Epidaure, Herault Canc Registry, F-34000 Montpellier, France
[9] CHU Grenoble, Dept HepatogastroEnterol, F-38043 Grenoble, France
关键词
colon cancer; management; population-based study; regional disparities;
D O I
10.1097/00008469-200502000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to assess possible regional disparities in the management of colon cancer in France. In 1995, 1605 patients with a colon cancer in eight areas covered by a population-based cancer registry were studied. Pre-therapeutic work-up, stage at diagnosis and therapeutic modalities were assessed. There were no differences between areas concerning the resection or the stage at diagnosis. The proportion of patients with a colonoscopy alone varied between 42.7 and 70.4% (P < 0.001). The use of both colonoscopy and barium enema was even more heterogeneous (extremes from 11.7 to 40.2%, P < 0.001). There were significant differences in the performance of abdominal computed tomography and tumour markers. The number of examined lymph nodes was lower than the recommendation in 47.3% of cases with extremes ranging from 36.9 to 60.9%. Adjuvant chemotherapy was performed on average in 49.4% of cases in stage II (in which it is not recommended) with extremes from 18.8 to 72.5% (P < 0.001) and in 79.6% of the cases in stage III (in which it is recommended) with extremes from 63.6 to 94.4% (P = 0.08). In conclusion, these results should alert practitioners and health care authorities in order to homogenize practices. (C) 2005 Lippincott Williams Wilkins.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 17 条
[1]  
DEBETTEGRATIEN M, 2002, GASTROENTEROL CLIN B, V26, pA45
[2]   Substantial variation in therapy for colorectal cancer across Europe: EUROCARE analysis of cancer registry data for 1987 [J].
Gatta, G ;
Sant, M ;
Coebergh, JW ;
Hakulinen, T .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (05) :831-835
[3]  
Jouve JL, 1998, GASTROEN CLIN BIOL, V22, P269
[4]  
KERJAN A, 1994, GASTROENTEROL CLIN B, V18, pA31
[5]  
LABIANCA R, 1995, LANCET, V345, P939
[6]  
LAUNOY G, 1991, REV EPIDEMIOL SANTE, V39, P523
[7]  
LAUNOY G, 1994, REV EPIDEMIOL SANTE, V44, P522
[8]   SURGICAL ADJUVANT THERAPY OF LARGE-BOWEL CARCINOMA - AN EVALUATION OF LEVAMISOLE AND THE COMBINATION OF LEVAMISOLE AND FLUOROURACIL [J].
LAURIE, JA ;
MOERTEL, CG ;
FLEMING, TR ;
WIEAND, HS ;
LEIGH, JE ;
RUBIN, J ;
MCCORMACK, GW ;
GERSTNER, JB ;
KROOK, JE ;
MALLIARD, J ;
TWITO, DI ;
MORTON, RF ;
TSCHETTER, LK ;
BARLOW, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) :1447-1456
[9]   Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' c colon cancer: Results from four national surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03, and C-04) [J].
Mamounas, E ;
Wieand, S ;
Wolmark, N ;
Bear, HD ;
Atkins, JN ;
Song, K ;
Jones, J ;
Rockette, H .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1349-1355
[10]   Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer [J].
Marsoni, S .
SEMINARS IN ONCOLOGY, 2001, 28 (01) :14-19